文献速递呼吸衰竭与机械通气中毒与环境急症

电子烟或雾化吸入相关肺损伤(EVALI):美国以外国际病例报告综述

E-cigarette or vaping-associated lung injury (EVALI): a review of international case reports from outside the United States of America.
PubMed 文献 · Clin Toxicol (Phila) · 2023-01-13
一句话结论美国以外17例EVALI病例中尼古丁/调味电子烟液暴露占100%,提示EVALI不限于大麻素产品,国际可能存在漏报。

该综述检索截至2021年2月的文献,纳入美国以外符合美国疾病控制与预防中心(CDC)「可能病例」标准的EVALI病例报告17例(来自13个国家),并与3个美国区域性病例系列共125例比较。美国以外病例尼古丁/调味电子烟液使用更常见(100% vs 58-67%),大麻素产品使用较少(24% vs 78-92%),重症监护入住率较低(24% vs 55-67%),但中位住院时间更长(15天 vs 5、6、7天)。作者认为EVALI不限于大麻素产品,国际报道的相似性提示可能存在漏报。

要点

  • 美国以外17例EVALI病例中尼古丁/调味电子烟液暴露报告率为100%,大麻素产品仅24%,提示EVALI不限于大麻素产品。
  • 美国以外病例重症监护入住率24%,低于美国3个病例系列的55-67%,但中位住院时间15天,长于美国的5、6、7天。
  • 所有队列最常见症状为呼吸困难(美国以外76% vs 美国85-91%)、咳嗽(59% vs 78-83%)和发热(47% vs 78-83%)。
  • 美国以外病例多数存在低氧(76% vs 美国69-86%),88%需住院(美国90-94%),与美国病例临床过程相似。
  • 作者认为美国以外病例支气管镜检查率更高、住院更长而ICU入住更少,可能反映国际临床医生经验不足。

适用人群与场景

  • 美国以外、使用电子烟或雾化装置后出现肺损伤、符合CDC「可能病例」标准的病例报告(17例,来自13个国家)。
  • 排除美国境内发生的病例;非美国病例若不符合CDC「可能病例」标准也被排除。

诊断标准与关键阈值

  • CDC「可能病例」标准:症状出现前90天内使用过雾化装置;胸部平片显示肺浸润或计算机断层扫描显示磨玻璃影;临床怀疑感染不是肺损伤的潜在原因;无其他可解释临床表现的合理医学过程。

研究设计与关键结果

  • 研究类型为病例报告综述,纳入美国以外17例EVALI病例(来自13个国家),并与3个美国区域性病例系列共125例比较(选择依据为这些比较因素数据完整)。
  • 男性占多数:美国以外76% vs 美国58-83%;中位年龄美国以外31岁 vs 美国27、19、27岁。
  • 尼古丁/调味电子烟液使用:美国以外100% vs 美国58-67%;大麻素产品使用:美国以外24% vs 美国78-92%。
  • 症状:呼吸困难美国以外76% vs 美国85-91%;咳嗽59% vs 78-83%;发热47% vs 78-83%。
  • 低氧:美国以外76% vs 美国69-86%;住院:88% vs 90-94%;重症监护入住:24% vs 55-67%;中位住院时间:15天 vs 5、6、7天。

证据类型、等级与局限

  • 证据类型:病例报告综述(国际病例报告汇总分析)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,美国以外病例尼古丁/调味电子烟液暴露的一致性可能低估了这些物质在EVALI中的作用。
  • 作者认为,美国以外队列住院时间更长、重症监护入住率更低、支气管镜检查率更高,可能提示国际临床医生经验不足。
  • 作者认为,美国以外病例胃肠道症状发生率更低的原因尚不清楚,也可能反映诊断意识较差。
  • 作者认为,美国以外与美国病例在人口学、临床特征和临床过程上的表面相似性,引起对EVALI国际漏报的担忧。

指南或共识出处

  • 美国疾病控制与预防中心(CDC)「可能病例」标准。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: E-cigarette or vaping-associated lung injury has been reported extensively throughout the United States without a corresponding number of international cases. Cannabinoid-based products have been implicated in the majority of cases.

OBJECTIVES: To collate published reports of E-cigarette or vaping-associated lung injury outside the United States and to identify the reasons behind the discrepancy in reported cases between the United States and the international community.

METHODS: PubMed and Healthcare Databases Advanced Search were used to identify published case reports of E-cigarette or vaping-associated lung injury prior to February 2021 using the search terms "e-cigarette", "e-cigarettes", "vaping", "vape" and, "lung injury", "pulmonary", "respiratory". Cases occurring in the United States were excluded. Non-United States case reports were excluded if they did not meet the Centers for Disease Control and Prevention "probable case" criteria. This requires use of a vaping device within 90 days of symptom onset, the presence of pulmonary infiltrates on plain film chest radiography or ground glass opacities on computerised tomography, clinical suspicion that infection was not the underlying cause of lung injury, and the absence of other plausible medical processes to account for the presentation. Patient demographics, nature of exposure, symptomatology and outcome were compared to 125 cases from three regional United States based case series, which were chosen on the basis of having complete data for these comparative factors.

RESULTS: Seventeen international cases from 13 countries were identified for analysis. There was a male predominance in both non-United States and United States cohorts (76% vs 58-83%), with a marginally higher median patient age in non-United States cases (31 vs 27, 19, 27 years). Reported use of nicotine/flavoured e-liquids was more common in non-United States cases (100% vs 58-67%), and use of cannabinoid-based products was less common (24% vs 78-92%). The most common symptoms across all cohorts were shortness of breath (76% vs 85-91%), cough (59% vs 78-83%) and fever (47% vs 78-83%). The majority of patients were hypoxic (76% vs 69-86%) and required hospital admission (88% vs 90-94%). Fewer of the non-United States patients required intensive care admission (24% vs 55-67%) though their median length of stay was longer (15 days vs 5, 6, 7 days).

DISCUSSION: Uniformity amongst non-United States cases in regards to nicotine based and/or flavoured e-liquid exposure may underestimate the role of these substances in e-cigarette or vaping-associated lung injury. This is consistent with prior United States based research demonstrating increased presentations to emergency departments prior to the recognised "outbreak" of e-cigarette or vaping-associated lung injury at a time of increased nicotine based e-liquid uptake. A longer length of hospital stay, lower rate of intensive care admission and a higher rate of bronchoscopy in the non-United States cohort could be indicative of clinician inexperience internationally. It is unclear why the non-United States cases also had a lower incidence of gastrointestinal symptoms however this may also be explained by poorer diagnostic awareness.

CONCLUSIONS: E-cigarette or vaping-associated lung injury is not limited to cannabinoid-based products. Apparent similarities in patient demographics, clinical features, and clinical course between non-United States and United States cases raise concern for underreporting of E-cigarette or vaping- associated lung injury internationally.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Sund LJ, Dargan PI, Archer JRH, et al. E-cigarette or vaping-associated lung injury (EVALI): a review of international case reports from outside the United States of America. Clin Toxicol (Phila). 2023. PMID: 36636876. doi:10.1080/15563650.2022.2160342

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。